Tumor Cells “Refuse Entry” and Actively Package for Export: Professor Zhuowei Liu’s Team Uncovers a Novel Mechanism of Resistance in Urothelial Carcinoma

Tumor Cells “Refuse Entry” and Actively Package for Export: Professor Zhuowei Liu’s Team Uncovers a Novel Mechanism of Resistance in Urothelial Carcinoma

On May 21, 2026, a research team led by Professor Zhuowei Liu, Dr. Zikun Ma, and Associate Research Fellow Xiaoyu Liang from Sun Yat-sen University Cancer Center published a study in Cancer Cell entitled “Endocytic Escape Drives Tumor Resistance to Antibody–Drug Conjugate Therapy.” The study systematically characterized the adaptive remodeling processes underlying resistance to antibody-drug conjugates (ADCs) using humanized mouse models, single-cell sequencing, and spatial transcriptomics.
 ASCO Voices from China | Professor Xinan Sheng and Professor Cuijian Zhang: First-Line Approval of Toripalimab for Metastatic Urothelial Carcinoma Marks a New Era for China-Developed Therapy and Reshapes the Treatment Landscape

 ASCO Voices from China | Professor Xinan Sheng and Professor Cuijian Zhang: First-Line Approval of Toripalimab for Metastatic Urothelial Carcinoma Marks a New Era for China-Developed Therapy and Reshapes the Treatment Landscape

For many years, platinum-based chemotherapy has remained the standard first-line treatment for urothelial carcinoma, yet outcomes have remained suboptimal. As targeted therapies and immunotherapy continue to advance rapidly, there is growing demand for more effective precision treatment strategies.
ASCO Voices from China | Professor Xuesong Li and Professor Qi Tang: Disitamab Vedotin Plus Radiotherapy Achieves a 95% 1-Year DFS Rate, Offering an Innovative Adjuvant Strategy for UTUC in China

ASCO Voices from China | Professor Xuesong Li and Professor Qi Tang: Disitamab Vedotin Plus Radiotherapy Achieves a 95% 1-Year DFS Rate, Offering an Innovative Adjuvant Strategy for UTUC in China

Upper tract urothelial carcinoma (UTUC) accounts for a substantially higher proportion of urothelial carcinoma cases in China than in Western populations. Although radical nephroureterectomy remains the standard treatment for UTUC, many patients become ineligible for cisplatin-based chemotherapy after surgery because of impaired renal function and other comorbidities. Furthermore, subgroup analyses from three major adjuvant immunotherapy trials have failed to demonstrate a significant disease-free survival (DFS) benefit in patients with UTUC, underscoring the urgent need for novel therapeutic strategies.
Professor Zhisong He and Professor Xin Yao: New Approval of Toripalimab for Urothelial Carcinoma, Chinese Clinical Evidence Powers CSCO Guidelines and Reshapes the National Treatment Landscape

Professor Zhisong He and Professor Xin Yao: New Approval of Toripalimab for Urothelial Carcinoma, Chinese Clinical Evidence Powers CSCO Guidelines and Reshapes the National Treatment Landscape

For nearly four decades, platinum-based chemotherapy has remained the standard first-line treatment for urothelial carcinoma (UC). However, its limitations—including modest survival outcomes and significant treatment-related toxicity—have persisted as major clinical challenges.
CURC & ARUF | Professor Linhui Wang: Addressing Complications in Retroperitoneal Surgery and Looking Ahead to the Future of Domestic Surgical Robots

CURC & ARUF | Professor Linhui Wang: Addressing Complications in Retroperitoneal Surgery and Looking Ahead to the Future of Domestic Surgical Robots

At this year’s CURC & ARUF Congress, Professor Linhui Wang from the First Affiliated Hospital of the Naval Medical University (Shanghai Changhai Hospital) served as Executive Chair of the meeting. During the Master Lecture session, he delivered a systematic analysis of the causes underlying postoperative abdominal wall bulging following retroperitoneal laparoscopic surgery. The congress also featured extensive live surgical demonstrations and dedicated sessions focused on the clinical application of domestically developed surgical robotic systems. In light of these key topics, Oncology Frontier invited Professor Wang for an in-depth interview.
CUDA Yanqi Lake Conference | Professor Ninghan Feng: Multidisciplinary Integration Empowering the Management of Complex Urologic Tumors — The Practice and Future of the MDT Model

CUDA Yanqi Lake Conference | Professor Ninghan Feng: Multidisciplinary Integration Empowering the Management of Complex Urologic Tumors — The Practice and Future of the MDT Model

As oncology treatment paradigms continue to evolve, the multidisciplinary team (MDT) approach has become a cornerstone of modern cancer care, particularly for the management of complex malignancies. In the field of urologic oncology, MDT care integrates expertise from surgery, medical oncology, radiation oncology, imaging, pathology, and other specialties to provide individualized, full-spectrum treatment strategies that significantly improve patient outcomes.
CUDA Yanqi Lake Conference | Exclusive Interview with Professor Hong Liao: In the Era of Precision Therapy for Prostate Cancer, How Do We Move from “Experience-Driven” to “Evidence-Driven” Care?

CUDA Yanqi Lake Conference | Exclusive Interview with Professor Hong Liao: In the Era of Precision Therapy for Prostate Cancer, How Do We Move from “Experience-Driven” to “Evidence-Driven” Care?

Prostate cancer is the second most commonly diagnosed malignancy and the fifth leading cause of cancer-related death among men worldwide. In recent years, with the rapid advancement of molecular biology technologies and the emergence of novel therapeutic agents, prostate cancer management has officially entered the era of precision medicine. Clinical decision-making is undergoing a profound transformation—from the traditional “one-size-fits-all” approach to individualized treatment strategies guided by precise staging and molecular profiling.
CUDA Yanqi Lake Conference | From Personal Mastery to Broader Impact: The Growth and Legacy of a Urologic Surgeon

CUDA Yanqi Lake Conference | From Personal Mastery to Broader Impact: The Growth and Legacy of a Urologic Surgeon

The 2026 Yanqi Lake Academic Conference for Urologists was successfully held in Beijing. During the meeting, Conference Chair Professor Nianzeng Xing, Vice President of the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences, shared his personal journey during the special session “From a Skilled Commander to a Strategic Leader.” He reflected on his transformation from a surgeon striving for technical perfection in the operating room to a discipline leader committed to cultivating teams and advancing the field as a whole.
CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

With the continuous emergence of novel therapies and landmark clinical evidence, the treatment landscape of urothelial carcinoma is undergoing profound transformation. Ahead of the 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference, Oncology Frontier – UroStream presents a special series of expert previews on major genitourinary oncology guidelines. In this issue, Professor Cuijian Zhang from Peking University First Hospital, Secretary of the CSCO Urothelial Carcinoma Expert Committee, discusses the evolution of the CSCO urothelial carcinoma guidelines, highlights potential updates in the upcoming edition, and shares insights into the clinical significance of emerging evidence and future directions in the field. His perspectives offer clinicians an early look at evolving treatment paradigms aimed at improving outcomes for Chinese patients.